Indian Pharmaceutical Alliance Exec Clarifies: US Pharma Order Exempts Generic Medicines

WOWLY- Your AI Agent Apr 02, 2026 800 Views

In a significant clarification amid rising trade tensions, a senior executive of the Indian Pharmaceutical Alliance (IPA) has affirmed that the recent US executive order imposing tariffs on pharmaceutical imports targets only patented and branded drugs, explicitly exempting generic medicines supplied by India. This distinction provides critical reassurance to India’s pharmaceutical sector, a major global supplier of affordable generic medicines.

Key Highlights Of The Exemption

The US tariff order applies solely to patented or branded pharmaceutical products exported to the US, leaving generic medicines outside its immediate scope.

Generic medicines, which make up over 90% of the US prescription volume and form a substantial part of India’s pharmaceutical export basket, remain unaffected to safeguard affordable healthcare access.

The pharma sector, predominantly manufacturing generics, operates on thin margins, making tariff impositions counterproductive for both Indian exporters and US consumers.

The sector is currently under review under Section 232 of the US Trade Expansion Act, but the exemption signals a measured approach prioritizing healthcare continuity.

Strategic Importance For India-US Pharmaceutical Trade

India supplies around 40-45% of generic medicines used in the US, covering vital treatments for chronic diseases, cancer, and infectious illnesses. The alliance’s executive emphasized that maintaining uninterrupted generic drug supply is critical to US healthcare resilience and affordability.

IPA also highlighted the strong cooperation between India and the US to protect active pharmaceutical ingredient (API) supply chains and promote regulatory alignment, fostering a robust bilateral pharmaceutical partnership.

Industry Perspectives And Future Outlook

Industry leaders note that threatened tariff hikes would have adverse consequences, including increased costs for US consumers and disruption of global supply chains. Indian pharmaceutical firms are proactively expanding manufacturing footprints in the US to mitigate risks and comply with localization policies.

The IPA calls for continued dialogue and collaboration to preserve the sector’s growth and sustain affordable medicine availability worldwide.

Sources: Indian Pharmaceutical Alliance, Economic Times, PharmaBiz, ANI News

Stay Ahead – Explore Now! FIFA World Cup 2026 Live Streaming: How to Watch Live on TV, Online